Difference between revisions of "Alemtuzumab (Campath)"
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Anti-CD52 antibody that is believed to cause antibody-dependent cell-mediated cytotoxicity of cells that express the CD52 antigen on their surface: B and T lymphocytes, most monocytes, macrophages, natural killer (NK) cells, and a subpopulation of granulocytes.<ref name="insert">[http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf Alemtuzumab (Campath) package insert]</ref><ref>[[Media:Alemtuzumab.pdf | Alemtuzumab (Campath) package insert (locally hosted backup)]]</ref><ref>[http://www.campath.com/ Campath manufacturer's website]</ref> | Class/mechanism: Anti-CD52 antibody that is believed to cause antibody-dependent cell-mediated cytotoxicity of cells that express the CD52 antigen on their surface: B and T lymphocytes, most monocytes, macrophages, natural killer (NK) cells, and a subpopulation of granulocytes.<ref name="insert">[http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf Alemtuzumab (Campath) package insert]</ref><ref>[[Media:Alemtuzumab.pdf | Alemtuzumab (Campath) package insert (locally hosted backup)]]</ref><ref>[http://www.campath.com/ Campath manufacturer's website]</ref> | ||
| Line 15: | Line 13: | ||
*Brief patient counseling information can be found at the end of page 2 of the [http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf#page=2 Alemtuzumab (Campath) package insert]<ref name="insert"></ref> | *Brief patient counseling information can be found at the end of page 2 of the [http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf#page=2 Alemtuzumab (Campath) package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/alemtuzumab-patient-drug-information Alemtuzumab (Campath) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/alemtuzumab-patient-drug-information Alemtuzumab (Campath) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/alemtuzumab-patient-drug-information Alemtuzumab (Campath) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/alemtuzumab-patient-drug-information Alemtuzumab (Campath) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | Campath, Campath-1H, Lemtrada, Mabcampath | ||
==References== | ==References== | ||
Revision as of 14:58, 1 April 2013
General information
Class/mechanism: Anti-CD52 antibody that is believed to cause antibody-dependent cell-mediated cytotoxicity of cells that express the CD52 antigen on their surface: B and T lymphocytes, most monocytes, macrophages, natural killer (NK) cells, and a subpopulation of granulocytes.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Alemtuzumab (Campath) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found at the end of page 2 of the Alemtuzumab (Campath) package insert[1]
- Alemtuzumab (Campath) patient drug information (UpToDate)[5]
Also known as
Campath, Campath-1H, Lemtrada, Mabcampath